A Phase 2 interventional study of TCD601 and Placebo in Diabetes Mellitus, Type 1, sponsored by ITB-Med LLC. Terminated at 26 sites in 5 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by ITB-Med LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 42 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 194th largest by enrollment of the 214 interventional ones that give a count, is one of 17 that started in 2023, is one of 25 in phase 2, and was the 240th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:
Sanofi · Sites in United Kingdom, Belgium, France and 3 more countries
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 16 more countries
Ages 1–35
Imperial College London · Sites in United Kingdom
Ages 18+
SAb Biotherapeutics, Inc. · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 5–40
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 31 · Phase 3 53 · Phase 4 18
First in 1997; this study’s year is marked. 17 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 214 interventional studies, 133 across the 54 observational. Of the 205 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 268 have an industry lead sponsor. The 10 most frequent:
ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
ITB-Med LLC has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
15 of the studies in Diabetes Mellitus, Type 1 with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
| NCT07583238University of NottinghamDiathermy On Diabetes Glucose Monitoring Effectiveness | 2027-02 |
| NCT06815081University of OxfordCapillary OGTT Study | 2027-02-28 |
Add all 15 to your calendar (.ics) → With an account.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered one of three doses of TCD601 over a 12 week treatment period.
Biological: TCD601
Placebo is administered over a 12 week treatment period.
Other: Placebo
Investigational Product
Comparator
Change from baseline in beta-cell function as compared to placebo at week 52.
Assess any changes in beta-cell function at the end of the study (week 52) for patients treated with TCD601 (study drug) compared to subjects treated with placebo (the comparator).
Time frame: 52 weeks
Assess the incidence and severity of adverse
Number of adverse events compared to placebo at week 52.
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Jul 2025, 30 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab
ITB-Med LLC